Management of Emetogenicity of Antibody-Drug Conjugates
Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.
Read More
Managing Toxicities in Short- and Long-Term Treatment with ADCs
Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.
Read More
Managing ILD and Pneumonitis Risk From ADCs
Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.
Read More
The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.
Read More
Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.
Read More
ADCs Targeting HER2+ GU Cancers
A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers
Read More
Impact of ADCs on Brain Metastases
A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.
Read More
ADCs Targeting HER2+ Lung Cancer
Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.
Read More
Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06
Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.
Read More
Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
Read More
ADCs Targeting HER2+ Gynecologic Cancers
Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.
Read More
ADCs Targeting HER2+ Breast Cancer
Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.
Read More
Assessing HER2 Status Across Tumor Types
Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
Read More
Anticipating Key Studies and Pipeline Treatments in mCRC Landscape
The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Read More
Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
Read More
Considerations for Platinum-based Therapy
Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
Read More
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Read More
Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
Read More